100 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Purchased by Future Financial Wealth Managment LLC

Future Financial Wealth Managment LLC acquired a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 100 shares of the pharmaceutical company’s stock, valued at approximately $42,000.

A number of other hedge funds also recently added to or reduced their stakes in VRTX. Venturi Wealth Management LLC raised its position in shares of Vertex Pharmaceuticals by 1.1% in the fourth quarter. Venturi Wealth Management LLC now owns 2,293 shares of the pharmaceutical company’s stock valued at $933,000 after buying an additional 24 shares during the last quarter. Nicholas Hoffman & Company LLC. raised its holdings in Vertex Pharmaceuticals by 3.9% in the 4th quarter. Nicholas Hoffman & Company LLC. now owns 636 shares of the pharmaceutical company’s stock valued at $259,000 after acquiring an additional 24 shares during the last quarter. Hohimer Wealth Management LLC lifted its stake in shares of Vertex Pharmaceuticals by 0.8% during the 4th quarter. Hohimer Wealth Management LLC now owns 2,932 shares of the pharmaceutical company’s stock worth $1,193,000 after purchasing an additional 24 shares during the period. Johnson Financial Group Inc. boosted its holdings in shares of Vertex Pharmaceuticals by 2.5% during the fourth quarter. Johnson Financial Group Inc. now owns 1,001 shares of the pharmaceutical company’s stock worth $407,000 after purchasing an additional 24 shares during the last quarter. Finally, Arthur M. Cohen & Associates LLC increased its stake in Vertex Pharmaceuticals by 3.2% in the fourth quarter. Arthur M. Cohen & Associates LLC now owns 800 shares of the pharmaceutical company’s stock valued at $326,000 after purchasing an additional 25 shares during the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Piper Sandler lifted their price target on Vertex Pharmaceuticals from $450.00 to $456.00 and gave the company an “overweight” rating in a report on Tuesday, May 7th. BMO Capital Markets boosted their target price on shares of Vertex Pharmaceuticals from $480.00 to $500.00 and gave the company an “outperform” rating in a report on Friday, May 31st. Canaccord Genuity Group reaffirmed a “sell” rating and set a $371.00 price target on shares of Vertex Pharmaceuticals in a research note on Friday, April 12th. Argus boosted their price objective on shares of Vertex Pharmaceuticals from $465.00 to $550.00 and gave the company a “buy” rating in a research note on Monday, June 17th. Finally, Wells Fargo & Company boosted their target price on Vertex Pharmaceuticals from $540.00 to $555.00 and gave the stock an “overweight” rating in a report on Monday. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and eighteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $448.61.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ:VRTX opened at $472.51 on Friday. The company has a market cap of $121.93 billion, a PE ratio of 30.66, a P/E/G ratio of 2.44 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $335.82 and a fifty-two week high of $486.42. The firm has a 50-day simple moving average of $441.82 and a 200 day simple moving average of $425.06. The company has a quick ratio of 3.29, a current ratio of 3.50 and a debt-to-equity ratio of 0.02.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share for the quarter, topping the consensus estimate of $3.66 by $1.10. The firm had revenue of $2.69 billion for the quarter, compared to analyst estimates of $2.58 billion. Vertex Pharmaceuticals had a net margin of 39.46% and a return on equity of 23.08%. Vertex Pharmaceuticals’s quarterly revenue was up 13.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.67 earnings per share. On average, sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.22 EPS for the current year.

Insider Buying and Selling

In related news, EVP Edward Morrow Atkinson III sold 7,288 shares of the stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $478.00, for a total transaction of $3,483,664.00. Following the sale, the executive vice president now owns 15,972 shares in the company, valued at $7,634,616. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CEO Reshma Kewalramani sold 1,565 shares of the company’s stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $457.00, for a total value of $715,205.00. Following the completion of the sale, the chief executive officer now directly owns 121,374 shares of the company’s stock, valued at approximately $55,467,918. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Edward Morrow Atkinson III sold 7,288 shares of the firm’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $478.00, for a total transaction of $3,483,664.00. Following the transaction, the executive vice president now owns 15,972 shares in the company, valued at approximately $7,634,616. The disclosure for this sale can be found here. Insiders have sold a total of 26,086 shares of company stock worth $11,983,266 over the last quarter. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.